The Moe Lab Group specializes in translational pathophysiology that spans from individual molecules, in vitro cell models, in vivo animal models, to metabolic human studies. The preclinical studies are jointly conducted with Ming Chang Hu’s and Donald Hilgemann’s laboratories, and the clinical studies are performed in collaboration with Khashayar Sakhaee and Naim Maalouf. The translational nature rest on attempt to elucidate pathobiology of human disease and eventual goal of developing agents for diagnostic, prognostic, and therapeutic applications in health care.

Two broad clinical areas are: 1. acute and chronic kidney disease, and 2. nephrolithiasis. The former category includes pathophysiologic mechanisms involving mineral metabolism mediating the acute kidney injury, acute kidney injury-to-chronic kidney disease transition, cardiovascular complications of chronic kidney disease. The latter category encompasses uric acid nephrolithiasis and the metabolic syndrome, renal acidification and citrate handling defects and propensity for calcium stones. Individual projects are described in more detail below.

In addition to scientific discovery, Moe and his collaborative investigator are dedicated to education and training. Moe has mentored 47 pre- and post-doctoral trainees over 30 years and 40 of them are in academic biomedical or industry scientific research-related fields. Moe also holds administrative positions as Director of the Charles and Jane Pak Center of Mineral Metabolism and Clinical Research (CMMCR) and Chief of the Division of Nephrology. Within the Pak CMMCR, Moe is active along with Dr. Charles Pak in the Neill Walsdorf Biotechnology Program that opens up novel commercial opportunities for translational diagnostic and therapeutic applications of the Center’s discoveries. Within the Nephrology Division, Moe is the Director of the O’Brien Kidney Research Center, and the T32 Post-Doctoral Fellow Training Grant.